JP4255211B2 - ヒトｂ細胞リンパ腫に関連した細胞表面糖タンパク質−ｕｌｂｐ、ｄｎａ及びポリペプチド - Google Patents

ヒトｂ細胞リンパ腫に関連した細胞表面糖タンパク質−ｕｌｂｐ、ｄｎａ及びポリペプチド Download PDF

Info

Publication number
JP4255211B2
JP4255211B2 JP2000539141A JP2000539141A JP4255211B2 JP 4255211 B2 JP4255211 B2 JP 4255211B2 JP 2000539141 A JP2000539141 A JP 2000539141A JP 2000539141 A JP2000539141 A JP 2000539141A JP 4255211 B2 JP4255211 B2 JP 4255211B2
Authority
JP
Japan
Prior art keywords
polypeptide
ulbp
seq
polypeptides
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000539141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002508183A5 (enExample
JP2002508183A (ja
Inventor
マルべルク，ヨルゲン，エイチ．
ファンスロー，ウィリアム，クリスチャン
コズマン，デビッド，ジョン
クビン，マレック
ジェイ． アーミテッジ，リチャード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of JP2002508183A publication Critical patent/JP2002508183A/ja
Publication of JP2002508183A5 publication Critical patent/JP2002508183A5/ja
Application granted granted Critical
Publication of JP4255211B2 publication Critical patent/JP4255211B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000539141A 1997-12-17 1998-12-17 ヒトｂ細胞リンパ腫に関連した細胞表面糖タンパク質−ｕｌｂｐ、ｄｎａ及びポリペプチド Expired - Fee Related JP4255211B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6985797P 1997-12-17 1997-12-17
US60/069,857 1997-12-17
US9294698P 1998-07-15 1998-07-15
US60/092,946 1998-07-15
PCT/US1998/027048 WO1999031241A1 (en) 1997-12-17 1998-12-17 Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides

Publications (3)

Publication Number Publication Date
JP2002508183A JP2002508183A (ja) 2002-03-19
JP2002508183A5 JP2002508183A5 (enExample) 2006-02-02
JP4255211B2 true JP4255211B2 (ja) 2009-04-15

Family

ID=26750491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000539141A Expired - Fee Related JP4255211B2 (ja) 1997-12-17 1998-12-17 ヒトｂ細胞リンパ腫に関連した細胞表面糖タンパク質−ｕｌｂｐ、ｄｎａ及びポリペプチド

Country Status (12)

Country Link
US (7) US6653447B1 (enExample)
EP (1) EP1037991B1 (enExample)
JP (1) JP4255211B2 (enExample)
AT (1) ATE305510T1 (enExample)
AU (1) AU742757C (enExample)
CA (1) CA2315251A1 (enExample)
DE (1) DE69831754T2 (enExample)
DK (1) DK1037991T3 (enExample)
ES (1) ES2251120T3 (enExample)
IL (2) IL136621A0 (enExample)
NZ (1) NZ505500A (enExample)
WO (1) WO1999031241A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2364941A1 (en) * 1999-03-15 2000-09-21 Takeda Chemical Industries, Ltd. Novel protein and its use
WO2002062997A1 (fr) * 2001-02-05 2002-08-15 Takeda Chemical Industries, Ltd. Nouvelle proteine et son utilisation
US6821522B2 (en) * 2001-05-31 2004-11-23 The Regents Of The University Of California Tumor Therapy
US7364890B2 (en) 2001-07-28 2008-04-29 Midwest Research Institute Thermal tolerant avicelase from Acidothermus cellulolyticus
MXPA04003057A (es) * 2001-10-04 2005-06-20 Immunex Corp Proteina 4 de enlace ul16.
CA2483343A1 (en) * 2002-04-22 2003-10-30 Fred Hutchinson Cancer Research Center Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
AU2003270063A1 (en) * 2002-09-04 2004-03-29 The Trustees Of The University Of Pennsylvania Immune cell receptor ligand and immune cell receptor
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
EP1413316A1 (en) * 2002-09-27 2004-04-28 Bruno Robert Bifunctional conjugates or fusion proteins
MXPA05010255A (es) * 2003-03-24 2005-12-14 Scripps Research Inst Vacunas de adn contra crecimiento tumoral y metodos de uso de las mismas.
US7666417B2 (en) * 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
GB0403491D0 (en) * 2004-02-17 2004-03-24 Univ Cambridge Tech Polypeptides, methods and means
US7998481B2 (en) 2004-04-05 2011-08-16 The Regents Of The University Of California Modulation of NKG2D for treating or preventing solid organ allograft rejection
DK1732588T3 (da) 2004-04-05 2009-10-12 Univ California Modulation af NKG2D
JP5774805B2 (ja) 2004-11-29 2015-09-09 セクエノム，インコーポレイティド メチル化ｄｎａを検出する方法、及びキット
US9074013B2 (en) 2004-11-29 2015-07-07 Sequenom, Inc. Means and methods for detecting methylated DNA
EP1909832A4 (en) * 2005-06-29 2010-01-13 Univ Miami ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY
US7846712B2 (en) 2006-06-01 2010-12-07 Alliance For Sustainable Energy, Llc L-arabinose fermenting yeast
WO2008103392A2 (en) 2007-02-21 2008-08-28 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cdid molecules
US9611313B2 (en) 2007-06-26 2017-04-04 University Of Miami Antibody-endostatin fusion protein and its variants
US20110038865A1 (en) * 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
US8070021B2 (en) * 2007-10-31 2011-12-06 Momentive Performance Materials Hydraulic container evacuator and method
EP2385980B1 (en) 2009-01-08 2018-04-18 Albert Einstein College of Medicine, Inc. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
WO2011127418A1 (en) 2010-04-09 2011-10-13 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
US10040853B2 (en) * 2011-09-09 2018-08-07 Fred Hutchinson Cancer Research Center Methods and compositions involving NKG2D inhibitors and cancer
US10093705B2 (en) 2011-09-13 2018-10-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
US20130156808A1 (en) * 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
WO2014015148A1 (en) 2012-07-19 2014-01-23 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
WO2015017529A2 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
JP6588024B2 (ja) 2013-10-28 2019-10-09 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 腫瘍溶解性ｈｓｖベクター
CA2935804A1 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
AU2015259053B2 (en) 2014-05-16 2020-12-24 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
US11117969B2 (en) * 2014-12-05 2021-09-14 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands
AU2015357578B2 (en) 2014-12-05 2018-11-08 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of NKG2D ligands
EP3368157B1 (en) 2015-10-29 2022-06-29 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
BR112018015390A2 (pt) 2016-01-27 2018-12-18 Oncorus, Inc. vetores virais oncolíticos e usos dos mesmos
WO2017218689A1 (en) 2016-06-14 2017-12-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
WO2018112636A1 (en) 2016-12-21 2018-06-28 Creatus Biosciences Inc. Method and organism expressing metschnikowia xylose transporters for increased xylose uptake
US10435721B2 (en) 2016-12-21 2019-10-08 Creatus Biosciences Inc. Xylitol producing metschnikowia species
JP7672196B2 (ja) 2017-03-14 2025-05-07 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
WO2019023483A1 (en) 2017-07-26 2019-01-31 Oncorus, Inc. ONCOLYTIC VIRAL VECTORS AND USES THEREOF
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
EP3775251A1 (en) 2018-03-26 2021-02-17 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
CN112074532B (zh) 2018-03-27 2025-02-28 修普霍斯生物科学有限公司 结合非天然NKG2D受体的非天然NKG2D配体的修饰的α1-α2结构域
WO2020051013A2 (en) * 2018-08-24 2020-03-12 The Trustees Of Columbia University In The City Of New York Anti-cd33 and nkg2d ligand chimeras for treatment of myeloid malignancies
CA3152547A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
JP2023548767A (ja) 2020-10-15 2023-11-21 アムジエン・インコーポレーテツド 抗体製造方法における相対不対グリカン
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
EP4413377A1 (en) 2021-10-05 2024-08-14 Amgen Inc. Fc-gamma receptor ii binding and glycan content
US20250161413A1 (en) 2022-02-16 2025-05-22 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
USRE38824E1 (en) * 1986-08-04 2005-10-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies against human herpes virus-6(HHV-6) and method of use
US5834229A (en) * 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5464771A (en) * 1994-04-29 1995-11-07 The United States Of America As Represented By The Secretary Of Agriculture Biologically pure culture of Actinomyces viscosus strain used for the bioremediation of chlorinated hydrocarbons
US6060241A (en) * 1996-04-05 2000-05-09 Kieta Holding Sa Compositions and methods relating to drug discovery and detection and treatment of gastrointestinal diseases
US5912415A (en) * 1996-05-16 1999-06-15 Regents Of The University Of Minnesota Arabidopsis spindly gene, methods of identification and use
US20030068623A1 (en) * 1997-06-16 2003-04-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Also Published As

Publication number Publication date
WO1999031241A1 (en) 1999-06-24
DE69831754T2 (de) 2006-06-29
US20040235058A1 (en) 2004-11-25
ATE305510T1 (de) 2005-10-15
IL136621A0 (en) 2001-06-14
NZ505500A (en) 2002-12-20
DK1037991T3 (da) 2006-01-09
US6458350B1 (en) 2002-10-01
US8410252B2 (en) 2013-04-02
ES2251120T3 (es) 2006-04-16
JP2002508183A (ja) 2002-03-19
AU742757B2 (en) 2002-01-10
US20110281789A1 (en) 2011-11-17
IL136621A (en) 2008-07-08
DE69831754D1 (de) 2006-02-09
AU2004599A (en) 1999-07-05
CA2315251A1 (en) 1999-06-24
US6653447B1 (en) 2003-11-25
US7193058B2 (en) 2007-03-20
EP1037991B1 (en) 2005-09-28
US20030147847A1 (en) 2003-08-07
AU742757C (en) 2007-05-17
US20090324597A1 (en) 2009-12-31
US7807796B2 (en) 2010-10-05
US6774224B2 (en) 2004-08-10
US20080008715A1 (en) 2008-01-10
US7427669B2 (en) 2008-09-23
EP1037991A1 (en) 2000-09-27

Similar Documents

Publication Publication Date Title
JP4255211B2 (ja) ヒトｂ細胞リンパ腫に関連した細胞表面糖タンパク質−ｕｌｂｐ、ｄｎａ及びポリペプチド
JP4409763B2 (ja) Ａｃｐｌｄｎａおよびポリペプチド
US7767793B2 (en) Antibodies to SIGIRR
JP3602442B2 (ja) ＩＬ−１δのＤＮＡおよびポリペプチド
US20080081043A1 (en) NK cell activation inducing ligand (NAIL) DNA and polypeptides, and use thereof
WO1999031256A2 (en) Cathepsin dc proteins, dna encoding the proteins, and their use in human cancer prognosis
AU753195B2 (en) TIGIRR DNA and polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080917

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090106

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090127

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120206

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120206

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130206

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130206

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140206

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees